Kurtović Tihana, Brgles Marija, Balija Maja Lang, Steinberger Stephanie, Sviben Dora, Marchetti-Deschmann Martina, Halassy Beata
Center for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Zagreb, Croatia.
Faculty of Technical Chemistry, Institute of Chemical Technologies and Analytics, TU Wien, Vienna, Austria.
J Venom Anim Toxins Incl Trop Dis. 2020 Jul 27;26:e20200025. doi: 10.1590/1678-9199-jvatitd-2020-0025. eCollection 2020.
Antivenoms are the only validated treatment against snakebite envenoming. Numerous drawbacks pertaining to their availability, safety and efficacy are becoming increasingly evident due to low sustainability of current productions. Technological innovation of procedures generating therapeutics of higher purity and better physicochemical characteristics at acceptable cost is necessary. The objective was to develop at laboratory scale a compact, feasible and economically viable platform for preparation of equine F(ab') antivenom against venom and to support it with efficiency data, to enable estimation of the process cost-effectiveness.
The principle of simultaneous caprylic acid precipitation and pepsin digestion has been implemented into plasma downstream processing. Balance between incomplete IgG breakdown, F(ab') over-digestion and loss of the active drug's protective efficacy was achieved by adjusting pepsin to a 1:30 substrate ratio (/) and setting pH at 3.2. Precipitation and digestion co-performance required 2 h-long incubation at 21 °C. Final polishing was accomplished by a combination of diafiltration and flow-through chromatography. neutralization potency of the F(ab') product against the venom's lethal toxicity was determined.
Only three consecutive steps, performed under finely tuned conditions, were sufficient for preservation of the highest process recovery with the overall yield of 74%, comparing favorably to others. At the same time, regulatory requirements were met. Final product was aggregate- and pepsin-free. Its composition profile was analyzed by mass spectrometry as a quality control check. Impurities, present in minor traces, were identified mostly as IgG/IgM fragments, contributing to active drug. Specific activity of the F(ab') preparation with respect to the plasma was increased 3.9-fold.
A highly streamlined mode for production of equine F(ab') antivenom was engineered. In addition to preservation of the highest process yield and fulfillment of the regulatory demands, performance simplicity and rapidity in the laboratory setting were demonstrated. Suitability for large-scale manufacturing appears promising.
抗蛇毒血清是唯一经过验证的治疗蛇咬伤中毒的药物。由于目前生产的可持续性较低,其在可用性、安全性和有效性方面的诸多缺点日益明显。有必要进行技术创新,以可接受的成本生产出纯度更高、理化特性更好的治疗药物。目的是在实验室规模上开发一个紧凑、可行且经济上可行的平台,用于制备抗蛇毒马F(ab') 片段,并提供效率数据以评估该工艺的成本效益。
辛酸沉淀和胃蛋白酶消化同时进行的原理已应用于血浆下游处理。通过将胃蛋白酶与底物的比例调整为1:30(/)并将pH值设定为3.2,实现了不完全IgG分解、F(ab')过度消化和活性药物保护效力损失之间的平衡。沉淀和消化同时进行需要在21℃下孵育2小时。最终的精制通过渗滤和流通色谱相结合来完成。测定了F(ab') 产物对蛇毒致死毒性的中和效力。
在精细调整的条件下仅进行三个连续步骤,就足以保持最高的工艺回收率,总收率为74%,优于其他方法。同时,满足了监管要求。最终产品不含聚集体和胃蛋白酶。通过质谱分析其组成概况作为质量控制检查。微量存在的杂质大多被鉴定为IgG/IgM片段,对活性药物有贡献。F(ab') 制剂相对于血浆的比活性提高了3.9倍。
设计了一种高度简化的抗蛇毒马F(ab') 片段生产模式。除了保持最高的工艺收率和满足监管要求外,还证明了在实验室环境中的操作简单性和快速性。其适用于大规模生产似乎很有前景。